Downregulation of lncRNA MALAT1 contributes to renal functional improvement after duodenal-jejunal bypass in a diabetic rat model

Wu, Dong; Cheng, Yugang; Huang, Xin; Zhong, Maiying; Liu, Shao-zhuang; Hu, Sanyuan

doi:10.1007/s13105-018-0636-y

Cited by 26 publications

(27 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…35 MALAT1 was also up-regulated in hyperglycemia and involved in hyperglycemia-induced dysfunction of retinal EC. 46 H 2 O 2 induced oxidative injury of ECs and up-regulated the expression of MALAT1. MALAT1 inhibited apoptosis of HUVECs by activating Nrf2 signaling pathway via downregulation of Keap1.…”

Section: The Malat1 and Endothelial Dysfunctionmentioning

confidence: 97%

See 1 more Smart Citation

The role of lncRNA MALAT1 in cardiovascular disease

Yan

Song

et al. 2019

IUBMB Life

View full text Add to dashboard Cite

Cardiovascular disease (CVD) is the first leading cause of death worldwide. Understanding the molecular mechanism of signaling pathways involved in pathology of CVD is benefit for targeted therapeutics. Recently, long non‐coding RNAs (lncRNAs) are found and involved in regulation of pathology of CVD at different levels. Among them, MALAT1 attracted more attention as it was profoundly expressed in endothelial cells or cardiomyocytes in response to the risk factors of CVD, such as hypoxia, high glucose, cytokine, and oxidative stress. In this review, we summarize recent progresses in research on the molecular mechanism of MALAT1 on regulating the pathophysiological processes of CVD as well as its potential therapeutic applications.

show abstract

Section: The Malat1 and Endothelial Dysfunctionmentioning

confidence: 97%

“…MiR‐22‐3p targeted CXC chemokine receptor 2, which played a key role in protecting the integrity of the endothelium . MALAT1 was also up‐regulated in hyperglycemia and involved in hyperglycemia‐induced dysfunction of retinal EC . H 2 O 2 induced oxidative injury of ECs and up‐regulated the expression of MALAT1.…”

Section: Malat1 and Vascular Diseasesmentioning

confidence: 99%

The role of lncRNA MALAT1 in cardiovascular disease

Yan

Song

et al. 2019

IUBMB Life

View full text Add to dashboard Cite

show abstract

“…In addition, specific reduction of renal miR-27a decreases renal fibrosis, and targeting miR-27a may represent a novel therapeutic approach for DN [105]. Besides, Wu et al found that downregulation of MALAT1 could improve renal function after duodenal-jejunal bypass in a diabetic rat model [106]. A recent research showed that silencing of lncRNA-GAS5 alleviated the HG-caused HK-2 cell toxicity [9].…”

Section: Therapeutic Potential Of Ncrna In Dnmentioning

confidence: 99%

Noncoding RNAs in Diabetic Nephropathy: Pathogenesis, Biomarkers, and Therapy

Mai

et al. 2020

Journal of Diabetes Research

View full text Add to dashboard Cite

The correlation between diabetes and systematic well-being on human life has long established. As a common complication of diabetes, the prevalence of diabetic nephropathy (DN) has been increasing globally. DN is known to be a major cause of end-stage kidney disease (ESKD). Till now, the molecular mechanisms for DN have not been fully explored and the effective therapies are still lacking. Noncoding RNAs are a class of RNAs produced by genome transcription that cannot be translated into proteins. It has been documented that ncRNAs participate in the pathogenesis of DN by regulating inflammation, apoptosis, autophagy, cell proliferation, and other pathological processes. In this review, the pathological roles and diagnostic and therapeutic potential of three types of ncRNAs (microRNA, long noncoding RNA, and circular RNA) in the progression of DN are summarized and illustrated.

show abstract

“…In DM, EC function can be impaired through several mechanisms, such as an alteration in signaling pathways, excessive oxidative stress, activation of pro-inflammatory factors and protein kinase C, and mitochondrial dysfunction [206]. Most recently, several genome-wide studies have been revealed the correlations of the functional involvement of different lncRNAs in ED and diabetes (Table 5) [55][56][57]67,68,75,79,207,208]. RNCR3 Up-regulated in DM and stimulates DM-induced retinal EC dysfunction through regulating RNCR3/ Kruppel like factor 2 (KLF2)/miR-185-5p pathway [79] One of the most common intergenic lncRNAs, named MALAT1, which is located on chromosome 11q13.1 and 7 kb in size, has been functionally identified and characterized in ED-associated diabetes [55].…”

Section: The Correlations Of Functional Involvement Of Lncrnas In Ed mentioning

confidence: 99%

A Brief Overview of lncRNAs in Endothelial Dysfunction-Associated Diseases: From Discovery to Characterization

Islam

Lai

2019

Epigenomes

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) are a novel class of regulatory RNA molecules and they are involved in many biological processes and disease developments. Several unique features of lncRNAs have been identified, such as tissue-and/or cell-specific expression pattern, which suggest that they could be potential candidates for therapeutic and diagnostic applications. More recently, the scope of lncRNA studies has been extended to endothelial biology research. Many of lncRNAs were found to be critically involved in the regulation of endothelial function and its associated disease progression. An improved understanding of endothelial biology can thus facilitate the discovery of novel biomarkers and therapeutic targets for endothelial dysfunction-associated diseases, such as abnormal angiogenesis, hypertension, diabetes, and atherosclerosis. Nevertheless, the underlying mechanism of lncRNA remains undefined in previous published studies. Therefore, in this review, we aimed to discuss the current methodologies for discovering and investigating the functions of lncRNAs and, in particular, to address the functions of selected lncRNAs in endothelial dysfunction-associated diseases.The disruptions of the auto-regulatory processes in endothelium, including decreased production and bioavailability of NO, impaired endothelial dependent-NO-mediated vascular relaxation, upregulated inflammatory genes expression level, dysregulated hemodynamic, adhesion molecules up-expression, excessive ROS production, and enhanced vascular endothelium permeability [3][4][5][6][7][8]. They are conclusively referred as "endothelial dysfunction (ED)". Subsequently, the dysfunction leads to the development and progression of different forms of vascular diseases [6]. Numerous studies have discovered significant correlations between ED and vascular-mediated diseases, such as angiogenesis, atherosclerosis, hypertension, diabetes, insulin resistance, obesity, etc. [6]. However, the underlying pathophysiology of ED and the correlations between functional roles of lncRNAs and vascular-mediated diseases remain unclear. Therefore, we aim to provide a brief playbook for the discovery and characterization of lncRNAs in ED-associated diseases and, in particular, to provide a concise overview of current knowledge on lncRNAs in ED-associated diseases. It is believed that with a better understanding the correlations of lncRNAs and ED-associated diseases, researches can make a positive impact on the development of novel biomarkers and therapeutic targets in ED-associated disease treatments. lncRNAs in the Regulation of Gene ExpressionAdvanced genome-and transcriptome-wide analyses discovered that <2% of human genome contains protein coding transcripts, while >75% of which were transcribed into noncoding RNAs (ncRNAs) and have no protein coding potentiality [9,10]. The ncRNAs can be broadly classified into two groups based upon their sizes: the short noncoding RNAs which are less than 200 nucleotides (nt) in length, such as small interfering RNAs (siRNAs), small nu...

show abstract

Downregulation of lncRNA MALAT1 contributes to renal functional improvement after duodenal-jejunal bypass in a diabetic rat model

Cited by 26 publications

References 40 publications

The role of lncRNA MALAT1 in cardiovascular disease

The role of lncRNA MALAT1 in cardiovascular disease

Noncoding RNAs in Diabetic Nephropathy: Pathogenesis, Biomarkers, and Therapy

A Brief Overview of lncRNAs in Endothelial Dysfunction-Associated Diseases: From Discovery to Characterization

Contact Info

Product

Resources

About